<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002154</url>
  </required_header>
  <id_info>
    <org_study_id>250A</org_study_id>
    <secondary_id>03-D95</secondary_id>
    <nct_id>NCT00002154</nct_id>
  </id_info>
  <brief_title>A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia</brief_title>
  <official_title>Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Dana Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give thioctic acid and&#xD;
      deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who&#xD;
      have mild to moderate dementia (a decline in their mental abilities).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic&#xD;
      acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active&#xD;
      drug on an open-label basis. Patients must have seven clinic visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>32</enrollment>
  <condition>Cognitive Disorders</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioctic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selegiline hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretrovirals provided dose has been stable for at least 6 weeks prior to study&#xD;
             entry.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  Mild to moderate cognitive impairment (problems with short term memory, concentration,&#xD;
             and feeling slowed down).&#xD;
&#xD;
          -  No active opportunistic CNS infection.&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior antiretrovirals provided dose has been stable for at least the past 6 weeks.&#xD;
&#xD;
          -  Prior thioctic acid or deprenyl.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Severe premorbid psychiatric illness including schizophrenia and major depression that&#xD;
             would interfere with study compliance.&#xD;
&#xD;
          -  CNS neoplasms.&#xD;
&#xD;
          -  Any other clinically significant condition or laboratory abnormality that would&#xD;
             preclude participation on study.&#xD;
&#xD;
          -  Current participation in other drug studies.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Chemotherapy for malignancy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of chronic neurological disorders such as serious head injury, documented&#xD;
             stroke, multiple sclerosis, uncontrolled epilepsy, Tourette's syndrome, and other&#xD;
             neurodegenerative processes such as Huntington's disease.&#xD;
&#xD;
          -  Prior participation in this study.&#xD;
&#xD;
          -  History of adverse reaction/allergy to thioctic acid or deprenyl.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other investigational drugs within 30 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212876965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univ</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Med Ctr</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Cognition Disorders</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Thioctic Acid</keyword>
  <keyword>Selegiline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Selegiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

